United States Antineoplastic Drugs Market Report 2018

United States Antineoplastic Drugs Market Report 2018

1 Antineoplastic Drugs Overview

1.1 Product Overview and Scope of Antineoplastic Drugs

1.2 Classification of Antineoplastic Drugs by Product Category

1.2.1 United States Antineoplastic Drugs Market Size (Sales Volume) Comparison by Type (2013-2025)

1.2.2 United States Antineoplastic Drugs Market Size (Sales Volume) Market Share by Type (Product Category) in 2017

1.2.3 Chemotherapeutic Agents

1.2.4 Biological/Immunotherapeutic Agents

1.2.5 Personalized Medicine

1.3 United States Antineoplastic Drugs Market by Application/End Users

1.3.1 United States Antineoplastic Drugs Market Size (Consumption) and Market Share Comparison by Application (2013-2025)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Cancer Rehabilitation Centers

1.3.5 Ambulatory Surgical Centers

1.4 United States Antineoplastic Drugs Market by Region

1.4.1 United States Antineoplastic Drugs Market Size (Value) Comparison by Region (2013-2025)

1.4.2 The West Antineoplastic Drugs Status and Prospect (2013-2025)

1.4.3 Southwest Antineoplastic Drugs Status and Prospect (2013-2025)

1.4.4 The Middle Atlantic Antineoplastic Drugs Status and Prospect (2013-2025)

1.4.5 New England Antineoplastic Drugs Status and Prospect (2013-2025)

1.4.6 The South Antineoplastic Drugs Status and Prospect (2013-2025)

1.4.7 The Midwest Antineoplastic Drugs Status and Prospect (2013-2025)

1.5 United States Market Size (Value and Volume) of Antineoplastic Drugs (2013-2025)

1.5.1 United States Antineoplastic Drugs Sales and Growth Rate (2013-2025)

1.5.2 United States Antineoplastic Drugs Revenue and Growth Rate (2013-2025)

2 United States Antineoplastic Drugs Market Competition by Players/Suppliers

2.1 United States Antineoplastic Drugs Sales and Market Share of Key Players/Suppliers (2013-2018)

2.2 United States Antineoplastic Drugs Revenue and Share by Players/Suppliers (2013-2018)

2.3 United States Antineoplastic Drugs Average Price by Players/Suppliers (2013-2018)

2.4 United States Antineoplastic Drugs Market Competitive Situation and Trends

2.4.1 United States Antineoplastic Drugs Market Concentration Rate

2.4.2 United States Antineoplastic Drugs Market Share of Top 3 and Top 5 Players/Suppliers

2.4.3 Mergers & Acquisitions, Expansion in United States Market

2.5 United States Players/Suppliers Antineoplastic Drugs Manufacturing Base Distribution, Sales Area, Product Type

3 United States Antineoplastic Drugs Sales (Volume) and Revenue (Value) by Region (2013-2018)

3.1 United States Antineoplastic Drugs Sales and Market Share by Region (2013-2018)

3.2 United States Antineoplastic Drugs Revenue and Market Share by Region (2013-2018)

3.3 United States Antineoplastic Drugs Price by Region (2013-2018)

4 United States Antineoplastic Drugs Sales (Volume) and Revenue (Value) by Type (Product Category) (2013-2018)

4.1 United States Antineoplastic Drugs Sales and Market Share by Type (Product Category) (2013-2018)

4.2 United States Antineoplastic Drugs Revenue and Market Share by Type (2013-2018)

4.3 United States Antineoplastic Drugs Price by Type (2013-2018)

4.4 United States Antineoplastic Drugs Sales Growth Rate by Type (2013-2018)

5 United States Antineoplastic Drugs Sales (Volume) by Application (2013-2018)

5.1 United States Antineoplastic Drugs Sales and Market Share by Application (2013-2018)

5.2 United States Antineoplastic Drugs Sales Growth Rate by Application (2013-2018)

5.3 Market Drivers and Opportunities

6 United States Antineoplastic Drugs Players/Suppliers Profiles and Sales Data

6.1 Hoffmann-La Roche

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Antineoplastic Drugs Product Category, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Hoffmann-La Roche Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.1.4 Main Business/Business Overview

6.2 Amgen

6.2.2 Antineoplastic Drugs Product Category, Application and Specification

6.2.2.1 Product A

6.2.2.2 Product B

6.2.3 Amgen Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.2.4 Main Business/Business Overview

6.3 Bristol-Myers Squibb

6.3.2 Antineoplastic Drugs Product Category, Application and Specification

6.3.2.1 Product A

6.3.2.2 Product B

6.3.3 Bristol-Myers Squibb Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.3.4 Main Business/Business Overview

6.4 Baxter Healthcare

6.4.2 Antineoplastic Drugs Product Category, Application and Specification

6.4.2.1 Product A

6.4.2.2 Product B

6.4.3 Baxter Healthcare Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.4.4 Main Business/Business Overview

6.5 Boehringer Ingelheim

6.5.2 Antineoplastic Drugs Product Category, Application and Specification

6.5.2.1 Product A

6.5.2.2 Product B

6.5.3 Boehringer Ingelheim Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.5.4 Main Business/Business Overview

6.6 Aspen Global

6.6.2 Antineoplastic Drugs Product Category, Application and Specification

6.6.2.1 Product A

6.6.2.2 Product B

6.6.3 Aspen Global Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.6.4 Main Business/Business Overview

6.7 Bayer AG

6.7.2 Antineoplastic Drugs Product Category, Application and Specification

6.7.2.1 Product A

6.7.2.2 Product B

6.7.3 Bayer AG Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.7.4 Main Business/Business Overview

6.8 Teva pharmaceutical Industries

6.8.2 Antineoplastic Drugs Product Category, Application and Specification

6.8.2.1 Product A

6.8.2.2 Product B

6.8.3 Teva pharmaceutical Industries Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.8.4 Main Business/Business Overview

6.9 Johnson & Johnson

6.9.2 Antineoplastic Drugs Product Category, Application and Specification

6.9.2.1 Product A

6.9.2.2 Product B

6.9.3 Johnson & Johnson Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.9.4 Main Business/Business Overview

6.10 Merc & Co.

6.10.2 Antineoplastic Drugs Product Category, Application and Specification

6.10.2.1 Product A

6.10.2.2 Product B

6.10.3 Merc & Co. Antineoplastic Drugs Sales, Revenue, Price and Gross Margin (2013-2018)

6.10.4 Main Business/Business Overview

6.11 Pfize

6.12 Accord Healthcare

6.13 Genentech

6.14 Lundbeck

6.15 AbbVie

7 Antineoplastic Drugs Manufacturing Cost Analysis

7.1 Antineoplastic Drugs Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Price Trend of Key Raw Materials

7.1.3 Key Suppliers of Raw Materials

7.1.4 Market Concentration Rate of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.2.1 Raw Materials

7.2.2 Labor Cost

7.2.3 Manufacturing Expenses

7.3 Manufacturing Process Analysis of Antineoplastic Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers

8.1 Antineoplastic Drugs Industrial Chain Analysis

8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Antineoplastic Drugs Major Manufacturers in 2017

8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

10 Market Effect Factors Analysis

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

11 United States Antineoplastic Drugs Market Size (Value and Volume) Forecast (2018-2025)

11.1 United States Antineoplastic Drugs Sales Volume, Revenue Forecast (2018-2025)

11.2 United States Antineoplastic Drugs Sales Volume Forecast by Type (2018-2025)

11.3 United States Antineoplastic Drugs Sales Volume Forecast by Application (2018-2025)

11.4 United States Antineoplastic Drugs Sales Volume Forecast by Region (2018-2025)

12 Research Findings and Conclusion

13 Appendix

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

Figure Product Picture of Antineoplastic Drugs

Figure United States Antineoplastic Drugs Market Size (K Units) by Type (2013-2025)

Figure United States Antineoplastic Drugs Sales Volume Market Share by Type (Product Category) in 2017

Figure Chemotherapeutic Agents Product Picture

Figure Biological/Immunotherapeutic Agents Product Picture

Figure Personalized Medicine Product Picture

Figure United States Antineoplastic Drugs Market Size (K Units) by Application (2013-2025)

Figure United States Sales Market Share of Antineoplastic Drugs by Application in 2017

Figure Hospitals Examples

Table Key Downstream Customer in Hospitals

Figure Clinics Examples

Table Key Downstream Customer in Clinics

Figure Cancer Rehabilitation Centers Examples

Table Key Downstream Customer in Cancer Rehabilitation Centers

Figure Ambulatory Surgical Centers Examples

Table Key Downstream Customer in Ambulatory Surgical Centers

Figure United States Antineoplastic Drugs Market Size (Million USD) by Region (2013-2025)

Figure The West Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure Southwest Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure The Middle Atlantic Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure New England Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure The South of US Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure The Midwest Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure United States Antineoplastic Drugs Sales (K Units) and Growth Rate (2013-2025)

Figure United States Antineoplastic Drugs Revenue (Million USD) and Growth Rate (2013-2025)

Figure United States Antineoplastic Drugs Market Major Players Product Sales Volume (K Units) (2013-2018)

Table United States Antineoplastic Drugs Sales (K Units) of Key Players/Suppliers (2013-2018)

Table United States Antineoplastic Drugs Sales Share by Players/Suppliers (2013-2018)

Figure 2017 United States Antineoplastic Drugs Sales Share by Players/Suppliers

Figure 2017 United States Antineoplastic Drugs Sales Share by Players/Suppliers

Figure United States Antineoplastic Drugs Market Major Players Product Revenue (Million USD) (2013-2018)

Table United States Antineoplastic Drugs Revenue (Million USD) by Players/Suppliers (2013-2018)

Table United States Antineoplastic Drugs Revenue Share by Players/Suppliers (2013-2018)

Figure 2017 United States Antineoplastic Drugs Revenue Share by Players/Suppliers

Figure 2017 United States Antineoplastic Drugs Revenue Share by Players/Suppliers

Table United States Market Antineoplastic Drugs Average Price (USD/Unit) of Key Players/Suppliers (2013-2018)

Figure United States Market Antineoplastic Drugs Average Price (USD/Unit) of Key Players/Suppliers in 2017

Figure United States Antineoplastic Drugs Market Share of Top 3 Players/Suppliers

Figure United States Antineoplastic Drugs Market Share of Top 5 Players/Suppliers

Table United States Players/Suppliers Antineoplastic Drugs Manufacturing Base Distribution and Sales Area

Table United States Players/Suppliers Antineoplastic Drugs Product Category

Table United States Antineoplastic Drugs Sales (K Units) by Region (2013-2018)

Table United States Antineoplastic Drugs Sales Share by Region (2013-2018)

Figure United States Antineoplastic Drugs Sales Share by Region (2013-2018)

Figure United States Antineoplastic Drugs Sales Market Share by Region in 2017

Table United States Antineoplastic Drugs Revenue (Million USD) and Market Share by Region (2013-2018)

Table United States Antineoplastic Drugs Revenue Share by Region (2013-2018)

Figure United States Antineoplastic Drugs Revenue Market Share by Region (2013-2018)

Figure United States Antineoplastic Drugs Revenue Market Share by Region in 2017

Table United States Antineoplastic Drugs Price (USD/Unit) by Region (2013-2018)

Table United States Antineoplastic Drugs Sales (K Units) by Type (2013-2018)

Table United States Antineoplastic Drugs Sales Share by Type (2013-2018)

Figure United States Antineoplastic Drugs Sales Share by Type (2013-2018)

Figure United States Antineoplastic Drugs Sales Market Share by Type in 2017

Table United States Antineoplastic Drugs Revenue (Million USD) and Market Share by Type (2013-2018)

Table United States Antineoplastic Drugs Revenue Share by Type (2013-2018)

Figure Revenue Market Share of Antineoplastic Drugs by Type (2013-2018)

Figure Revenue Market Share of Antineoplastic Drugs by Type in 2017

Table United States Antineoplastic Drugs Price (USD/Unit) by Types (2013-2018)

Figure United States Antineoplastic Drugs Sales Growth Rate by Type (2013-2018)

Table United States Antineoplastic Drugs Sales (K Units) by Application (2013-2018)

Table United States Antineoplastic Drugs Sales Market Share by Application (2013-2018)

Figure United States Antineoplastic Drugs Sales Market Share by Application (2013-2018)

Figure United States Antineoplastic Drugs Sales Market Share by Application in 2017

Table United States Antineoplastic Drugs Sales Growth Rate by Application (2013-2018)

Figure United States Antineoplastic Drugs Sales Growth Rate by Application (2013-2018)

Table Hoffmann-La Roche Basic Information List

Table Hoffmann-La Roche Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Hoffmann-La Roche Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Hoffmann-La Roche Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Hoffmann-La Roche Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Amgen Basic Information List

Table Amgen Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Amgen Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Amgen Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Amgen Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Bristol-Myers Squibb Basic Information List

Table Bristol-Myers Squibb Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Bristol-Myers Squibb Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Bristol-Myers Squibb Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Bristol-Myers Squibb Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Baxter Healthcare Basic Information List

Table Baxter Healthcare Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Baxter Healthcare Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Baxter Healthcare Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Baxter Healthcare Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Boehringer Ingelheim Basic Information List

Table Boehringer Ingelheim Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Boehringer Ingelheim Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Boehringer Ingelheim Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Boehringer Ingelheim Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Aspen Global Basic Information List

Table Aspen Global Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Aspen Global Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Aspen Global Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Aspen Global Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Bayer AG Basic Information List

Table Bayer AG Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Bayer AG Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Bayer AG Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Bayer AG Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Teva pharmaceutical Industries Basic Information List

Table Teva pharmaceutical Industries Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Teva pharmaceutical Industries Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Teva pharmaceutical Industries Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Teva pharmaceutical Industries Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Johnson & Johnson Basic Information List

Table Johnson & Johnson Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Johnson & Johnson Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Johnson & Johnson Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Johnson & Johnson Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Merc & Co. Basic Information List

Table Merc & Co. Antineoplastic Drugs Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2013-2018)

Figure Merc & Co. Antineoplastic Drugs Sales Growth Rate (2013-2018)

Figure Merc & Co. Antineoplastic Drugs Sales Market Share in United States (2013-2018)

Figure Merc & Co. Antineoplastic Drugs Revenue Market Share in United States (2013-2018)

Table Pfize Basic Information List

Table Accord Healthcare Basic Information List

Table Genentech Basic Information List

Table Lundbeck Basic Information List

Table AbbVie Basic Information List

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Antineoplastic Drugs

Figure Manufacturing Process Analysis of Antineoplastic Drugs

Figure Antineoplastic Drugs Industrial Chain Analysis

Table Raw Materials Sources of Antineoplastic Drugs Major Players/Suppliers in 2017

Table Major Buyers of Antineoplastic Drugs

Table Distributors/Traders List

Figure United States Antineoplastic Drugs Sales Volume (K Units) and Growth Rate Forecast (2018-2025)

Figure United States Antineoplastic Drugs Revenue (Million USD) and Growth Rate Forecast (2018-2025)

Figure United States Antineoplastic Drugs Price (USD/Unit) Trend Forecast (2018-2025)

Table United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Type (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Type (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Type in 2025

Table United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Application (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Application (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Application in 2025

Table United States Antineoplastic Drugs Sales Volume (K Units) Forecast by Region (2018-2025)

Table United States Antineoplastic Drugs Sales Volume Share Forecast by Region (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume Share Forecast by Region (2018-2025)

Figure United States Antineoplastic Drugs Sales Volume Share Forecast by Region in 2025

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources